MWNA
LENZ

Marshall Wace North America’s LENZ Therapeutics LENZ Stock Holding History

Marshall Wace North America’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,235
Closed -$1.13M – 1768
2021
Q2 		$1.13M Buy
+5,235
New +$912K ﹤0.01% 977

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace North America's LENZ Position: Q3 2021 in Review

Marshall Wace North America sold out of LENZ Therapeutics (LENZ) in Q3 2021, closing a stake of 5,235 shares — an estimated $1.13M sold.

Marshall Wace North America first reported a position in LENZ in Q2 2021 and held it in 1 quarter. The position peaked at $1.13M in Q2 2021. 60 funds tracked by Wall St. Rank hold LENZ as of Q3 2021.

  • Marshall Wace North America reported no remaining LENZ Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 5,235 LENZ Therapeutics shares in Q3 2021, an estimated $1.13M.
  • Marshall Wace North America first reported a position in LENZ Therapeutics in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's LENZ Therapeutics position peaked at $1.13M in Q2 2021.
  • 60 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.